ketorolac has been researched along with Dry Eye in 3 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to compare the topical anti-inflammatory effects of the nonselective cyclooxygenase (COX) inhibitor, ketorolac, with the selective COX-2 inhibitor, nimesulide, in an animal model of dry eye in albino rabbits." | 7.74 | Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits. ( El-Gohary, AA; El-Hossary, GG; El-Shazly, AH; El-Shazly, LH, 2008) |
| "Patients (n = 52) with clinically diagnosed dry eye were randomized to receive either cyclosporin-A monotherapy twice-daily (BID) or a BID adjunctive regimen of ketorolac, followed by the instillation of cyclosporin-A 10 min later." | 5.12 | Ketorolac during the induction phase of cyclosporin-A therapy. ( Schechter, BA, 2006) |
| "To evaluate the effect of the topical steroid, fluorometholone, and the non-steroidal anti-inflammatory drugs (NSAIDs), nepafenac and ketorolac, on inflammatory cytokine expression of the ocular surface in the botulium toxin B-induced murine dry eye model." | 3.78 | Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. ( Chuck, RS; Zhang, C; Zhu, L, 2012) |
| "The purpose of this study was to compare the topical anti-inflammatory effects of the nonselective cyclooxygenase (COX) inhibitor, ketorolac, with the selective COX-2 inhibitor, nimesulide, in an animal model of dry eye in albino rabbits." | 3.74 | Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits. ( El-Gohary, AA; El-Hossary, GG; El-Shazly, AH; El-Shazly, LH, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Shazly, AH | 1 |
| El-Gohary, AA | 1 |
| El-Shazly, LH | 1 |
| El-Hossary, GG | 1 |
| Zhu, L | 1 |
| Zhang, C | 1 |
| Chuck, RS | 1 |
| Schechter, BA | 1 |
1 trial available for ketorolac and Dry Eye
| Article | Year |
|---|---|
Ketorolac during the induction phase of cyclosporin-A therapy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Drug Therapy, Combination; Dry Eye Synd | 2006 |
2 other studies available for ketorolac and Dry Eye
| Article | Year |
|---|---|
Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits.
Topics: Administration, Topical; Animals; Atropine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxyg | 2008 |
Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Botuli | 2012 |